Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival


EGE ç., AKBULUT M., ZEKİOĞLU O. , ÖZDEMİR N.

ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol.284, no.5, pp.1231-1239, 2011 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 284 Issue: 5
  • Publication Date: 2011
  • Doi Number: 10.1007/s00404-010-1766-9
  • Title of Journal : ARCHIVES OF GYNECOLOGY AND OBSTETRICS
  • Page Numbers: pp.1231-1239
  • Keywords: Galectin-3, Heparanase, Serous endometrial carcinoma, Endometrial hyperplasia, HUMAN BREAST-CARCINOMA, PROSTATE-CANCER, GENE-EXPRESSION, HEPATOCELLULAR-CARCINOMA, THYROID-CARCINOMA, EPITHELIAL-CELLS, METASTASIS, PROGRESSION, APOPTOSIS, GROWTH

Abstract

Inhibitors of tumor angiogenesis and metastasis are emerging as important new drug candidates for cancer therapy. Galectin-3 and heparanase have been shown to function in tumor progression and metastatic spread. Both of them exert pleiotropic effects; proliferation, cell migration, differentiation and tissue remodeling. The aim of this study was to investigate heparanase and galectin-3 expression in endometrioid and serous carcinomas of the endometrium and their relation with well-known prognostic factors, in addition to estrogen, progesterone, C-erbB-2, Ki-67 and p53.